

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
NHLBI-MDS	National Myelodysplastic Syndromes (MDS) Study	Registry	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1925	Randomized, Phase III Study of Early Intervention With Venetoclax And Obinutuzumab Versus Delayed Therapy With Venetoclax And Obinutuzumab In Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A041702	A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL1521	A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL15P1	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

AALL1631	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AALL1732	COG-AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-Lly	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AAML1531	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACCL16N1CD	Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL	Cancer Care Delivery	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ALLIANCE: A041501	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A041701	A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S1318	<p>A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)</p>	Treatment	<p>CRCWM Physician Investigators</p>	<p>CRCWM (616) 391-1230 www.crcwm.org</p>
S1712	<p>A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease</p>	Treatment	<p>CRCWM Physician Investigators</p>	<p>CRCWM (616) 391-1230 www.crcwm.org</p>
Connect® MDS and AML	<p>The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry</p>	Registry	<p>CHCWM Physician Investigators</p>	<p>CHCWM (616) 954-9800 www.chcwm.com</p>
USC 9L-16-3	<p>A Phase II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, An Immune Checkpoint Inhibitor, in Patients with Intermediate or High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia</p>	Treatment	<p>CHCWM Physician Investigators</p>	<p>CHCWM (616) 954-9800 www.chcwm.com</p>